BioMarin Pharmaceuticals BMRN Business Segments — Other segment expense, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's business segments — other segment expense, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's business segments — other segment expense, net?
- BioMarin Pharmaceuticals (BMRN) reported business segments — other segment expense, net of $28.6M in Q1 2026.
- How has BioMarin Pharmaceuticals's business segments — other segment expense, net changed year-over-year?
- BioMarin Pharmaceuticals's business segments — other segment expense, net decreased by 33.6% year-over-year, from $43.05M to $28.6M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — other segment expense, net?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — other segment expense, net has grown at a 55.2% compound annual growth rate (CAGR), from -$21.39M to $79.96M.
- What does business segments — other segment expense, net mean?
- The net total of miscellaneous income and expenses unique to this business segment.
- How do you interpret business segments — other segment expense, net?
- Fluctuations often reflect non-recurring events or specific contractual arrangements, requiring analysis of the underlying drivers.
- How does business segments — other segment expense, net compare across companies?
- Comparable to 'other operating income/expense' line items in segment financial disclosures.